vedolizumab (entyvio) Report issue

Biologics mAb Approved FDA First in Class Fast Track FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Millennium Pharmaceuticals, Inc. for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α4β7. Blocking the α4β7 integrin results in gut-selective anti-inflammatory activity.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$2407.4538

United States

$4573.8400 - $6255.2200
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

entyvio | ldp02 | ldp-02 | mln0002 | mln-0002 | mln02 | mln-02 | vedolizumab

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue